Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Aclaris Therapeutics stock

ACRS
US00461U1051
A1412H

Price

0
Today +/-
-0
Today %
-0 %

Aclaris Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Aclaris Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Aclaris Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Aclaris Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Aclaris Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Aclaris Therapeutics Stock Price History

DateAclaris Therapeutics Price
1/17/20250 undefined
1/16/20252.51 undefined
1/15/20252.51 undefined
1/14/20252.50 undefined
1/13/20252.48 undefined
1/10/20252.47 undefined
1/8/20252.46 undefined
1/7/20252.50 undefined
1/6/20252.53 undefined
1/3/20252.60 undefined
1/2/20252.48 undefined
12/31/20242.48 undefined
12/30/20242.48 undefined
12/27/20242.73 undefined
12/26/20242.92 undefined
12/24/20242.90 undefined
12/23/20242.89 undefined
12/20/20242.72 undefined
12/19/20242.77 undefined

Aclaris Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Aclaris Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Aclaris Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Aclaris Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Aclaris Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Aclaris Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Aclaris Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Aclaris Therapeutics’s growth potential.

Aclaris Therapeutics Revenue, EBIT and net profit per share

DateAclaris Therapeutics RevenueAclaris Therapeutics EBITAclaris Therapeutics Net Income
2029e142.76 M undefined19.68 M undefined-50.64 M undefined
2028e39.22 M undefined-68.52 M undefined-62.29 M undefined
2027e11.42 M undefined-78.55 M undefined-58.65 M undefined
2026e8.46 M undefined-80.87 M undefined-42.26 M undefined
2025e9.77 M undefined-62.68 M undefined-32.66 M undefined
2024e11.84 M undefined-62.26 M undefined-50.15 M undefined
202331.25 M undefined-89.41 M undefined-88.48 M undefined
202229.75 M undefined-85.15 M undefined-86.91 M undefined
20216.76 M undefined-65.38 M undefined-90.87 M undefined
20206.48 M undefined-50.91 M undefined-51.02 M undefined
20194.23 M undefined-92.56 M undefined-161.35 M undefined
20186.15 M undefined-84.78 M undefined-132.74 M undefined
20171.68 M undefined-72.42 M undefined-68.52 M undefined
20160 undefined-48.57 M undefined-48.08 M undefined
20150 undefined-20.67 M undefined-23.13 M undefined
20140 undefined-8.53 M undefined-10.57 M undefined
20130 undefined-5.26 M undefined-6.98 M undefined

Aclaris Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
000016466293111981139142
-----500.00-33.3350.00-383.336.90-64.52-18.18-11.1137.50254.55264.10
----1,300.0016.67325.0016.6733.3358.6241.94118.18144.44162.50118.1833.339.15
0000010121713000000
-6-10-23-48-68-132-161-51-90-86-88-50-32-42-58-62-50
-66.67130.00108.7041.6794.1221.97-68.3276.47-4.442.33-43.18-36.0031.2538.106.90-19.35
36.7636.7620.1621.4228.132.9141.3242.5456.7365.2169.81000000
-----------------
Details

Keystats

ⓘ

Revenue and Growth

The Aclaris Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Aclaris Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (k)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (k)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20132014201520162017201820192020202120222023
                     
13.316.184.9137.2193.91687554.1191.4217.6119.11
0000500600700800600500298
00000000000
00000000000
0.10.21.71.35.9118.12.61313.59.45
13.416.386.6138.5200.3179.683.857.5205231.6128.86
00.50.40.52.22.37.25.84.83.85.48
0.80.57.236.91500034.212.262.77
00000000000
00007.37.37.27.1770.27
000018.518.500000
0000.10.3680.10.40.10.10.03
0.817.637.543.396.114.513.346.123.168.55
14.217.394.2176243.6275.798.370.8251.1254.7197.41
                     
2336.7000000000
00135.5260.7384.9507.4523.5542.3793880.8928.08
-9.2-20.7-42.8-90.9-159.4-292.2-453.5-504.5-595.4-682.3-770.8
00-0.1-0.3-0.2-0.1-0.1-0.1-0.2-0.9-0.11
00000000000
13.81692.6169.5225.3215.169.937.7197.4197.6157.18
0.41.30.82.87.814.89.95.31010.48.88
00.20.71.836.144.65.1612.93
000.11.61.86.48.457.95.69.15
00000000000
00001001001000000
0.41.51.66.212.727.422.414.9232230.95
0000029.9010.7000
00005005005004004004000
0000.44.92.65.47.230.634.79.27
0000.45.4335.918.33135.19.27
0.41.51.66.618.160.428.333.25457.140.23
14.217.594.2176.1243.4275.598.270.9251.4254.7197.4
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Aclaris Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Aclaris Therapeutics's financial health and stability.

Assets

Aclaris Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Aclaris Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Aclaris Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Aclaris Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20132014201520162017201820192020202120222023
-5-8-20-48-68-132-161-51-90-86-88
00000161000
0000-1000000
00-1409-2-2-1-19
002152840772453340
00000000000
00000000000
-4-7-20-34-54-100-96-38-52-67-78
0000-1-1-1000-1
-4-1-76-61-5591056-1671246
-4-1-76-61-54101076-1671347
00000000000
000000-3010-1100
01096116100100072397226
01096116100128-30182257226
000002800-300
00000000000
-91020-936-21-13517-5
-4.92-8.06-20.88-34.83-55.9-102.17-98.06-39.08-52.44-68.18-79.63
00000000000

Aclaris Therapeutics stock margins

The Aclaris Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Aclaris Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Aclaris Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Aclaris Therapeutics's sales revenue. A higher gross margin percentage indicates that the Aclaris Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Aclaris Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Aclaris Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Aclaris Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Aclaris Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Aclaris Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Aclaris Therapeutics Margin History

Aclaris Therapeutics Gross marginAclaris Therapeutics Profit marginAclaris Therapeutics EBIT marginAclaris Therapeutics Profit margin
2029e42.14 %13.78 %-35.47 %
2028e42.14 %-174.73 %-158.85 %
2027e42.14 %-687.97 %-513.72 %
2026e42.14 %-955.96 %-499.5 %
2025e42.14 %-641.55 %-334.34 %
2024e42.14 %-525.78 %-423.5 %
202342.14 %-286.13 %-283.15 %
202259.8 %-286.22 %-292.13 %
202130.33 %-967.16 %-1,344.23 %
202020.83 %-785.65 %-787.35 %
20194.02 %-2,188.18 %-3,814.42 %
201829.59 %-1,378.54 %-2,158.37 %
201728.57 %-4,310.71 %-4,078.57 %
201642.14 %0 %0 %
201542.14 %0 %0 %
201442.14 %0 %0 %
201342.14 %0 %0 %

Aclaris Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Aclaris Therapeutics earnings per share therefore indicates how much revenue Aclaris Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Aclaris Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Aclaris Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Aclaris Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Aclaris Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Aclaris Therapeutics Revenue, EBIT and net profit per share

DateAclaris Therapeutics Sales per ShareAclaris Therapeutics EBIT per shareAclaris Therapeutics Earnings per Share
2029e2 undefined0 undefined-0.71 undefined
2028e0.55 undefined0 undefined-0.87 undefined
2027e0.16 undefined0 undefined-0.82 undefined
2026e0.12 undefined0 undefined-0.59 undefined
2025e0.14 undefined0 undefined-0.46 undefined
2024e0.17 undefined0 undefined-0.7 undefined
20230.45 undefined-1.28 undefined-1.27 undefined
20220.46 undefined-1.31 undefined-1.33 undefined
20210.12 undefined-1.15 undefined-1.6 undefined
20200.15 undefined-1.2 undefined-1.2 undefined
20190.1 undefined-2.24 undefined-3.9 undefined
20180.19 undefined-2.58 undefined-4.03 undefined
20170.06 undefined-2.58 undefined-2.44 undefined
20160 undefined-2.27 undefined-2.24 undefined
20150 undefined-1.03 undefined-1.15 undefined
20140 undefined-0.23 undefined-0.29 undefined
20130 undefined-0.14 undefined-0.19 undefined

Aclaris Therapeutics business model

Aclaris Therapeutics Inc was founded in 2012 and is based in Wayne, Pennsylvania. The company focuses on the development and marketing of innovative solutions for the treatment of skin problems and other diseases that significantly impact the quality of life of those affected. Aclaris' business model is based on the research and development of new therapies that address various medical problems and conditions. The company employs a combination of internal research projects and the acquisition of promising products and pipeline assets from third-party companies. Aclaris is divided into different business segments that focus on various medical issues and conditions. One important area is dermatology, where the company has developed several innovative products and therapies. This includes RHOFADE® (Oxymetazoline Hydrochloride), a topical medication for the treatment of rosacea. The novel product A-101, used for the treatment of seborrheic keratosis, has also been established in the market. In the field of oncological dermatology, Aclaris has a promising pipeline focused on the development of drugs for the treatment of actinic keratosis, basal cell carcinoma, squamous cell carcinoma, and melanoma. The company collaborates closely with scientists and research institutions to develop innovative solutions that can revolutionize the pharmaceutical market. Another area that Aclaris focuses on is immunology, including the development of new therapies for the treatment of inflammatory diseases such as alopecia areata, an autoimmune disease that causes hair loss. Aclaris has already made significant progress in this area and is conducting clinical studies to demonstrate the effectiveness of its products in treating this condition. In addition to the development of innovative therapies, Aclaris also collaborates closely with other companies and research institutions to develop platform technologies that can accelerate and simplify the development of new drugs. This includes state-of-the-art analytical methods and the development of new molecules that specifically target certain diseases. Aclaris' business model has proven successful in recent years. The company combines internal research projects with the acquisition of promising pipeline assets from third-party companies to expand its portfolio and pipeline. This approach allows Aclaris to quickly respond to changing market conditions and patient needs, positioning themselves as a leading player in the pharmaceutical market. Aclaris' products have already improved many lives and successfully treated numerous patients with various medical problems. The company aims to achieve sustainable improvement in the quality of life of patients and continuously develop new innovative solutions to secure a leading position in the highly competitive pharmaceutical market. Aclaris Therapeutics is one of the most popular companies on Eulerpool.com.

Aclaris Therapeutics SWOT Analysis

Strengths

1. Strong Research and Development Capabilities: Aclaris Therapeutics Inc has a robust research and development division, enabling them to continuously innovate and develop new products.

2. Diverse Portfolio of Products: The company offers a wide range of therapeutic products across various medical conditions, providing a diverse revenue stream.

3. Established Brand Presence: Aclaris Therapeutics Inc has built a reputable brand image in the pharmaceutical industry, which attracts both customers and potential investors.

Weaknesses

1. Dependency on a Few Key Products: Aclaris Therapeutics Inc relies heavily on a small number of key products for a significant portion of their revenue, making them vulnerable to market fluctuations or patent expirations.

2. Limited Global Presence: The company's market reach is primarily limited to certain regions, which restricts the potential for expansion and exposes them to regional economic challenges.

3. Compliance and Regulatory Risks: Aclaris Therapeutics Inc operates in a highly regulated industry, and any non-compliance issues or regulatory obstacles could disrupt their operations or delay product approvals.

Opportunities

1. Growing Demand for Innovative Therapies: The increasing demand for advanced treatment options presents an opportunity for Aclaris Therapeutics Inc to develop and market new therapies.

2. Expansion into Emerging Markets: The company can capitalize on untapped markets in developing countries, offering their products and services to a wider customer base.

3. Strategic Partnerships and Collaborations: Forming partnerships with other pharmaceutical companies or research institutions can enhance Aclaris Therapeutics Inc's capabilities and accelerate product development.

Threats

1. Intense Competition: Aclaris Therapeutics Inc faces fierce competition from other established pharmaceutical companies, which can adversely impact market share and pricing.

2. Intellectual Property Infringement: The risk of patent infringement or unauthorized replication of their products by competitors poses a significant threat to Aclaris Therapeutics Inc's profitability.

3. Economic Volatility and Healthcare Reforms: Unpredictable economic conditions and potential changes in healthcare regulations could affect the affordability and accessibility of Aclaris Therapeutics Inc's products.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Aclaris Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Aclaris Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Aclaris Therapeutics shares outstanding

The number of shares was Aclaris Therapeutics in 2024 — This indicates how many shares 69.809 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Aclaris Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Aclaris Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Aclaris Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Aclaris Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Aclaris Therapeutics.

Aclaris Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-0.01 -0.11  (-1,796.55 %)2024 Q3
6/30/2024-0.21 -0.15  (28.06 %)2024 Q2
3/31/2024-0.29 -0.24  (17.64 %)2024 Q1
12/31/2023-0.35 -0.02  (94.31 %)2023 Q4
9/30/2023-0.49 -0.41  (16.26 %)2023 Q3
6/30/2023-0.46 -0.42  (8.5 %)2023 Q2
3/31/2023-0.45 -0.4  (10.41 %)2023 Q1
12/31/2022-0.45 -0.41  (9.79 %)2022 Q4
9/30/2022-0.4 -0.3  (25.67 %)2022 Q3
6/30/2022-0.37 -0.31  (15.18 %)2022 Q2
1
2
3
4

Eulerpool ESG Scorecard© for the Aclaris Therapeutics stock

Eulerpool World ESG Rating (EESG©)

48/ 100

🌱 Environment

49

👫 Social

70

🏛️ Governance

25

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Aclaris Therapeutics shareholders

%
Name
Stocks
Change
Date
18.18302 % BML Capital Management LLC12,988,1343,592,2006/30/2024
6.56244 % The Vanguard Group, Inc.4,687,551-242,2246/30/2024
4.64820 % D. E. Shaw & Co., L.P.3,320,20637,2246/30/2024
4.20775 % Millennium Management LLC3,005,598-331,2529/30/2024
3.85482 % Rock Springs Capital Management LP2,753,49506/30/2024
3.56989 % Two Sigma Investments, LP2,549,972-246,8586/30/2024
2.69837 % Stonepine Capital Management, LLC1,927,4461,927,4466/30/2024
2.67878 % Acadian Asset Management LLC1,913,449-221,9186/30/2024
2.67813 % Trium Capital LLP1,912,99020,9409/30/2024
2.67386 % BlackRock Institutional Trust Company, N.A.1,909,938-2,874,1076/30/2024
1
2
3
4
5
...
10

Aclaris Therapeutics Executives and Management Board

Dr. Neal Walker

(53)
Aclaris Therapeutics Non-Executive Chairman of the Board, President, Interim Chief Executive Officer, Co-Founder (since 2012)
Compensation 5.84 M

Dr. Joseph Monahan

(67)
Aclaris Therapeutics Chief Scientific Officer
Compensation 2.82 M

Mr. Christopher Molineaux

(57)
Aclaris Therapeutics Lead Independent Director
Compensation 296,554

Dr. Maxine Gowen

(65)
Aclaris Therapeutics Independent Director
Compensation 285,054

Dr. Anand Mehra

(47)
Aclaris Therapeutics Independent Director
Compensation 277,554
1
2
3

Aclaris Therapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Novan Stock
Novan
SupplierCustomer0,860,910,900,160,590,62
1

Most common questions regarding Aclaris Therapeutics

What values and corporate philosophy does Aclaris Therapeutics represent?

Aclaris Therapeutics Inc represents values of innovation, commitment, and patient-centricity in the field of biopharmaceuticals. The company is dedicated to developing and commercializing innovative therapies to address unmet medical needs. With a focus on dermatology and immunology, Aclaris is driven by the desire to improve patients' lives by providing effective and safe treatment options. Their corporate philosophy emphasizes collaboration, scientific rigor, and a passion for transforming the way diseases are treated. Aclaris is committed to advancing medical research, fostering partnerships, and delivering value to patients, healthcare professionals, and shareholders through its cutting-edge therapeutic solutions.

In which countries and regions is Aclaris Therapeutics primarily present?

Aclaris Therapeutics Inc is primarily present in the United States. This pharmaceutical company focuses on the discovery, development, and commercialization of innovative therapies. Aclaris Therapeutics Inc has its headquarters in Wayne, Pennsylvania, and operates primarily within the United States. With a strong emphasis on dermatology, Aclaris Therapeutics Inc has made significant advancements in treating various skin conditions. Renowned for its expertise and groundbreaking research, Aclaris Therapeutics Inc continues to revolutionize the field of dermatology through cutting-edge therapies and solutions.

What significant milestones has the company Aclaris Therapeutics achieved?

Aclaris Therapeutics Inc has achieved several significant milestones in its history. The company successfully launched its key product, Eskata, in 2018, which is an FDA-approved treatment for raised seborrheic keratoses, a common skin condition. Additionally, Aclaris Therapeutics developed a novel JAK inhibitor, ATI-501, for the treatment of alopecia areata, which successfully completed Phase 2 clinical trials. Another notable milestone for the company was the acquisition of Confluence Life Sciences, Inc, which expanded its pipeline and research capabilities. Aclaris Therapeutics Inc has demonstrated its commitment to advancing innovative treatments and expanding its portfolio in the field of dermatology.

What is the history and background of the company Aclaris Therapeutics?

Aclaris Therapeutics Inc is a renowned pharmaceutical company specializing in developing and commercializing innovative therapies for dermatological conditions. Founded in 2012, Aclaris has rapidly gained recognition for its groundbreaking research and dedication to improving patients' lives. With its headquarters located in Pennsylvania, USA, the company has established a strong presence in the global biopharmaceutical industry. Aclaris focuses on discovering and developing novel drugs that target various skin diseases, such as alopecia, psoriasis, and vitiligo. Through continuous dedication and a passion for scientific advancement, Aclaris Therapeutics Inc has become a trusted name in the field of dermatology.

Who are the main competitors of Aclaris Therapeutics in the market?

The main competitors of Aclaris Therapeutics Inc in the market are leading pharmaceutical companies specializing in dermatology and aesthetics. Some notable competitors include AbbVie Inc., Allergan plc, Novartis AG, Pfizer Inc., and Johnson & Johnson. These companies have a strong presence in the market and offer a range of innovative products for various dermatological conditions. However, Aclaris Therapeutics Inc has carved a niche for itself by focusing on developing and commercializing novel therapies for immuno-inflammatory diseases.

In which industries is Aclaris Therapeutics primarily active?

Aclaris Therapeutics Inc is primarily active in the pharmaceutical and biotechnology industries.

What is the business model of Aclaris Therapeutics?

The business model of Aclaris Therapeutics Inc. is focused on developing and commercializing innovative therapies to address dermatological conditions. By leveraging its expertise in drug discovery and clinical development, Aclaris aims to transform the treatment landscape for various skin diseases. The company's portfolio includes both investigative compounds and marketed products targeting diseases such as alopecia areata, vitiligo, and common warts. Through strategic partnerships, research collaborations, and product sales, Aclaris Therapeutics Inc. aims to provide effective solutions and improve the quality of life for patients suffering from dermatological disorders.

What is the P/E ratio of Aclaris Therapeutics 2025?

The P/E ratio cannot be calculated for Aclaris Therapeutics at the moment.

What is the P/S ratio of Aclaris Therapeutics 2025?

The P/S cannot be calculated for Aclaris Therapeutics currently.

What is the Quality Investing of Aclaris Therapeutics?

The Quality Investing for Aclaris Therapeutics is 5/10.

What is the revenue of Aclaris Therapeutics 2025?

The expected Aclaris Therapeutics revenue is 9.77 M USD.

How high is the profit of Aclaris Therapeutics 2025?

The expected Aclaris Therapeutics profit is -32.66 M USD.

What is the business model of Aclaris Therapeutics

Aclaris Therapeutics Inc is an American biopharmaceutical company focused on developing integrated therapy programs for skin diseases. The company is headquartered in Wayne, Pennsylvania, USA, and was founded in 2012.

What is the Aclaris Therapeutics dividend?

Aclaris Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Aclaris Therapeutics pay dividends?

The dividend cannot currently be calculated for Aclaris Therapeutics or the company does not pay out a dividend.

What is the Aclaris Therapeutics ISIN?

The ISIN of Aclaris Therapeutics is US00461U1051.

What is the Aclaris Therapeutics WKN?

The WKN of Aclaris Therapeutics is A1412H.

What is the Aclaris Therapeutics ticker?

The ticker of Aclaris Therapeutics is ACRS.

How much dividend does Aclaris Therapeutics pay?

Over the past 12 months, Aclaris Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aclaris Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Aclaris Therapeutics?

The current dividend yield of Aclaris Therapeutics is .

When does Aclaris Therapeutics pay dividends?

Aclaris Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Aclaris Therapeutics?

Aclaris Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Aclaris Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aclaris Therapeutics located?

Aclaris Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aclaris Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aclaris Therapeutics from 1/17/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/17/2025.

When did Aclaris Therapeutics pay the last dividend?

The last dividend was paid out on 1/17/2025.

What was the dividend of Aclaris Therapeutics in the year 2024?

In the year 2024, Aclaris Therapeutics distributed 0 USD as dividends.

In which currency does Aclaris Therapeutics pay out the dividend?

The dividends of Aclaris Therapeutics are distributed in USD.

All fundamentals about Aclaris Therapeutics

Our stock analysis for Aclaris Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aclaris Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.